A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps1112
Abstract: TPS1112Background: CDK4/6i, including palbociclib and ribociclib (R), have demonstrated remarkable benefit in progression free survival (PFS) in patients (pts) with HR+, HER2- MBC with anti-estrogen therapy. Switching between anti-estrogen therapies at disease progression is standard… read more here.
Keywords: trial; fulvestrant; her2 mbc; inhibition ... See more keywords
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Management and Research"
DOI: 10.2147/cmar.s137772
Abstract: Fulvestrant is the first selective estrogen receptor (ER) downregulator available in clinical practice. It is a pure antiestrogen with no agonistic effects, leading to degradation of ER alpha, with activity in tamoxifen-resistant breast cancer (BC)… read more here.
Keywords: combination; fulvestrant; treatment; breast cancer ... See more keywords